Difference between revisions of "Team:Munich/Applied Design"

Problem

Traditionally, infectious diseases are diagnosed by cell culture or PCR-based methods. As these techniques require expensive infrastructure, trained personal, and time, the current practice suffers from three main problems. First, diagnosis is not available everywhere, and therefore pathogens are usually detected in central clinics, rather than at the point-of-care. Second, diagnosis is not accessible to everyone, especially in developing countries proper medical supply is often lacking, due to the high costs. And third, diagnosis is not available within a few hours, which can lead to negligence of laboratory tests, resulting in premature prescription of antibiotics, the primary reason for the recrudescence of resistant bacteria strains.

Current solutions

Most point-of-care tests that are currently established on the market, like pregnancy tests, are based on antibodies targeting certain metabolites. These tests are therefore restricted to one specific application and require long and expensive design cycles for the development of new tests for other applications.¹ Recently, qPCR-based systems were developed that provide a more universal solution for highly automated nucleic-acid detection. According to doctors without borders (link) there are two cartridge-based systems that are currently employed for in-field applications. GeneXpert allows the detection of MRSA in patient samples, and Alere™ q provides an automated bench top platform for nucleic acid testing in any healthcare setting.

These qPCR- and ELISA-based methods represent a significant advance in the portability and usability of point-of-care testing. However, these tests cost around 10$ for consumables and several thousands of $ for the device. This is too high for applications in developing countries for which doctors without borders calls a price of less than 1$ per test.

Improvement + integrating + disrupting on current solutions

We developed CascAID to combine the portability, affordability, and usability of point-of-care tests with the universality and sensitivity of PCR-based nucleic acid detection. We achieve this by using the tools of synthetic biology to minimize hardware requirements and by supplying CascAID in a low-cost paper-based format. Due to the rapid, software-aided design of crRNA, CascAID can be easily adapted to a variety of targets - from bacterial infections and rapidly evolving viral epidemics to cancer-associated mutations. Additionally, the Cas13a enzyme was shown to find targets with a single-nucleotide specificity, superior to PCR-based methods. (CascAID can be entirely conducted on-site by the doctor or patient and therefore reduces the logistic complexity, drastically hastening the diagnostic process.)